Dogwood Therapeutics DWTX Deferred Finance Costs Noncurrent Net
Deferred Finance Costs Noncurrent Net at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredFinanceCostsNoncurrentNet.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's deferred finance costs noncurrent net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's deferred finance costs noncurrent net?
- Dogwood Therapeutics (DWTX) reported deferred finance costs noncurrent net of $159K in Q1 2026.
- What does deferred finance costs noncurrent net mean?
- This represents the unamortized portion of costs directly attributable to the issuance of long-term debt or financing arrangements, net of accumulated amortization. These costs are capitalized and recognized as expense over the term of the associated financing instrument. It serves as an indicator of the company's historical reliance on external debt financing and the ongoing impact of financing activities on future earnings.